Skip to main content

Biopharma

Connexius Genome Editing Asia 2027

Date
14–15 September 2027
Location
Singapore

Overview

Genome editing is rapidly transforming the possibilities of modern medicine, enabling scientists to precisely modify DNA and RNA and opening new approaches to treating genetic disorders, cancer, infectious diseases and other complex conditions. Across Asia-Pacific, advances in CRISPR-Cas systems, base and prime editing, functional genomics, cell engineering and novel delivery technologies are accelerating the journey from fundamental research towards therapeutic development.

The region is already demonstrating significant momentum. In Singapore, the A*STAR Genome Institute of Singapore (GIS) is developing next-generation CRISPR technologies for DNA and RNA engineering, including new editing systems and viral and non-viral delivery approaches for targeted therapeutics. Singapore researchers have also demonstrated an AAV-delivered CRISPR-Cas13 approach targeting the EV-A71 virus, highlighting the potential of genome editing beyond inherited genetic diseases.

Momentum is also growing across the wider Asian therapeutic ecosystem. China introduced new rules in 2026 governing investigator-initiated cell and gene therapy trials, reflecting the increasing movement of advanced genetic technologies towards clinical evaluation. At the same time, Asia's growing genomics capabilities are providing increasingly rich datasets and technologies for understanding disease biology and identifying new therapeutic targets.

Taking place on 14–15 September 2027 in Singapore, Connexius Genome Editing Asia 2027 will bring together leading scientists, biopharma and biotech companies, therapeutic developers, research institutes and technology providers from across Asia-Pacific. The conference will explore the genome editing journey from CRISPR and next-generation editing technologies through delivery, cell engineering, safety and off-target analysis, preclinical development, CMC and clinical translation — creating a platform to exchange scientific expertise, discover enabling technologies and advance the next generation of genome editing therapeutics.

Programme

Day 1 — Tuesday 14 September 2027

  • 08:30

    Registration & Welcome Coffee

  • 09:00

    Chairperson's Welcome & Opening Remarks

  • 09:10

    SESSION I - THE FUTURE OF GENOME EDITING & THERAPEUTICS

  • 10:25

    Morning Networking Break & Exhibition Viewing

  • 11:10

    SESSION II: NEXT-GENERATION CRISPR & EDITING TECHNOLOGIES

  • 12:25

    Networking Lunch & Exhibition Viewing

  • 13:40

    SESSION III: BASE EDITING, PRIME EDITING & PRECISION GENOME ENGINEERING

  • 14:55

    Afternoon Networking Coffee & Exhibition Viewing

  • 15:40

    SESSION IV: TRANSLATING GENOME EDITING FROM DISCOVERY TO PRECLINICAL DEVELOPMENT

  • 17:00

    End of Day 1 — Connexius Genome Editing Asia 2027, Networking Reception

Day 2 — Wednesday 15 September 2027

  • 09:10

    SESSION V: DELIVERY TECHNOLOGIES FOR GENOME EDITING

  • 10:25

    Morning Networking Break & Exhibition Viewing

  • 11:10

    SESSION VI: CELL ENGINEERING & EX VIVO GENOME EDITING

  • 12:25

    Networking Lunch & Exhibition Viewing

  • 13:40

    SESSION VII: SAFETY, ANALYTICS & CMC DEVELOPMENT

  • 14:55

    Afternoon Networking Coffee & Exhibition Viewing

  • 15:40

    SESSION VIII: CLINICAL TRANSLATION, REGULATORY & COMMERCIALISATION

  • 17:00

    End of Conference

Who Attends

By Company Profile

  • Biopharma, Biotech & Cell/Gene Therapy Companies & Big Pharma45%
  • Universities, research institutes & hospitals25%
  • Solution & service providers25%
  • Government, regulators, investors & associations5%

By Job Function

  • Genome Editing / CRISPR / Gene Editing R&D20%
  • Cell & Gene Therapy / Cell Engineering15%
  • Discovery Biology / Functional Genomics15%
  • Translational & Preclinical Development12%
  • Delivery / Vector Development10%
  • Analytical Development / Safety / Bioinformatics10%
  • CMC / Process Development / Manufacturing8%
  • Business Development / Licensing / Partnerships10%

By Country / Market

  • Singapore30%
  • China, Hong Kong & Taiwan20%
  • Japan & South Korea15%
  • Southeast Asia excluding Singapore10%
  • India10%
  • Australia & New Zealand10%
  • US, Europe & other international5%

Want to Sponsor This Event?

Explore sponsorship opportunities and discover how your brand can connect with key decision-makers across the industry.

Speak with our Sponsorship Team

Roshinee Singh

Head of Business Development

roshinee.singh@connexiusgroup.com

Jack Baclaan

Business Development Manager

jack.baclaan@connexiusgroup.com

Jumarie Albit

Business Development Manager

jumarie.albit@connexiusgroup.com

Register

Contact us for group bookings of three or more delegates.

Delegate Category
Super Early Bird Rate
Valid until 31st May 2027
Early Bird Rate
Valid 31st July 2027
Standard Rate
Biopharma, Big Pharma, Academics, Research Institutes & GovernmentSGD 699SGD 899SGD 1,099
Service & Solution ProviderSGD 2,049SGD 2,249SGD 2,449

INSIGHTS

  • BiopharmaMarket insight

    Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?

    The first approved CRISPR therapy proved that genome editing can work as a medicine. Asia, home to a large share of the world's patients with inherited blood disorders and a fast-growing research base, is now moving from discovery towards the clinic. This article looks at where the region stands, what is holding it back and what to watch next.

    Read more: Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?
  • BiopharmaIndustry article

    Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia

    On 12 November 2026, Eppendorf SE broke ground on a new production facility at Bandar Cassia Technology Park in Penang. The EUR 40 million investment is the company's first manufacturing operation in Southeast Asia and will produce selected products from its Centrifuges & Instruments portfolio for laboratories worldwide, with production starting gradually in 2028.

    Read more: Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia
  • BiopharmaMarket insight

    Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?

    Biologics manufacturing productivity depends on more than installed bioreactor volume. This article compares four 2,000 L single-use bioreactors with one 10,000 L stainless-steel reactor and examines how turnaround time, utilisation, titre, downstream capacity and manufacturing strategy can determine annual output.

    Read more: Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?